-
Stocks mostly rise tracking earnings, US-Iran hopes
-
Alarm at German airport after drone found near Ukrainian plane, mid-air incident
-
Pakistan team reaches base camp with body of renowned climber killed in avalanche
-
Salah arrives in Turkey for Trabzonspor talks
-
Ceuta warns of 'unsustainable' situation for child migrants after influx
-
Embattled FIFA chief Infantino holds emergency talks with directors
-
SpaceX rocket stage believed to have slammed into Moon
-
Russian barrage on Kyiv kills 17 as Ukraine fails to down single missile
-
India monsoon floods, landslides kill more than 100 since July: officials
-
'Lost': Migrants despair after Britain expels them back to France
-
South Korea pro baseball league cancels games over heatwave
-
Cathay Pacific's profit soars 71% despite Iran war driving up fuel costs
-
Taiwan probes 17 China-funded firms over high-tech talent poaching
-
Russian barrage on Ukraine kills 15, wounds dozens more
-
Trump warns Iran to open Hormuz or get 'hit very hard'
-
South Korea police raid Starbucks HQ over 'Tank Day' fiasco
-
Factories shed workers in Bangladesh garment sector
-
Tech back in fashion as Asian markets extend rebound
-
North Korea warns of 'military options' over Japan rearmament
-
Total eclipse gives scientists chance to probe Sun's mysteries
-
Tiny light, big dream: Harvesting power from soil in Japan
-
What to know about the total solar eclipse on August 12
-
Trump admin to review 'closed' AI models before release: reports
-
'Like the end of the world': the eclipse chasers flocking to Spain
-
De Minaur fights past Duckworth in all-Aussie Montreal battle
-
Taiwan begins military drills as China pressure grows
-
High bills, cheap panels drive a Philippine solar surge
-
UK mansion where 'listeners' spied on Nazi generals becomes museum
-
Russian barrage on Ukraine kills 2, wounds dozens more
-
Sabalenka tops Uchijima in WTA Toronto opener
-
RE Royalties Announces Third Investment in Solaris Energy's Portfolio and Letter of Intent for Expanded Royalty Partnership for a Further US$62.7 Million
-
Alcaraz withdraws from Cincinnati Masters with wrist injury
-
Kgatlana strikes as South Africa reach WAFCON quarter-finals
-
SpaceX revenue jumps 92% in first earnings report, but shares slide
-
Pakistan close on series-levelling win against West Indies
-
US eyes Hormuz deal 'today or tomorrow' as ship sinks in Red Sea
-
Paramount CEO says politics fueling Warner Bros. merger battle
-
SpaceX revenue jumps 92% in first earnings report
-
Trump's sale of access to Truth Social raises eyebrows
-
New commissioner Berg wants to take MLS to 'next level'
-
SpaceX rocket stage expected to slam into Moon
-
Colombian ex-guerrillas fear for future under hardline president
-
US hopeful Hormuz strait deal will be done 'today or tomorrow'
-
Tsitsipas comeback continues with Montreal first-round win
-
Michigan primary puts Democratic divide on the ballot
-
Swiatek fends off Bejlek to reach Toronto third round
-
South Africa captain Kolisi to make Test return in Argentina
-
Reusser romps to overall lead at Tour de France Femmes
-
Cuba's famed resilience comes at a growing mental cost
-
McDonald's reports slower US sales in 2nd quarter
Trump administration does about face on autism treatment
The Trump administration did an about-face Tuesday on an autism treatment it had promoted with great fanfare.
It had said back in September it would approve use of a drug called leucovorin -- synthetic vitamin B9 -- to treat the disorder.
But on Tuesday the Food and Drug Administration backed off, citing insufficient evidence that it works for the condition.
The initial announcement came from Health Secretary Robert F. Kennedy Jr, who for decades has spread debunked claims that vaccines cause autism.
Kennedy touted leucovorin, usually used to alleviate chemotherapy side effects, as an "exciting therapy" that could help children with autism, a disorder whose symptoms vary widely across a spectrum.
"This gives hope to the many parents with autistic children that it may be possible to improve their lives," President Donald Trump said in September at a press conference.
At the event he gave sweeping, unsubstantiated advice on autism, such as insisting that pregnant women should "tough it out" and avoid Tylenol over an unproven link to autism -- statements slammed by scientists.
Studies on a small number of patients have suggested that taking leucovorin can help ease some communication or personal-relations problems linked to autism, but experts say this issue needs more study.
On Tuesday the FDA said it was in fact approving use of leucovorin for a rare condition called cerebral folate deficiency but not for autism.
The Trump administration's touting of it for autism ran the risk of raising false hopes, dozens of autism specialists said at the time in a joint letter.
"We don't have sufficient data to say that we could establish efficacy for autism more broadly," an FDA official told NBC News.
"It'll be up to patients to talk with their physicians to see if that might be right for them," said the official, whose name was not given.
X.Matos--PC